Acquired resistance to immune checkpoint blockade therapies

Xianda Zhao; Dechen Wangmo; Matthew Robertson; Subbaya Subramanian

doi:10.3390/cancers12051161

Acquired resistance to immune checkpoint blockade therapies

Xianda Zhao, Dechen Wangmo, Matthew Robertson, Subbaya Subramanian

Surgery

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.

Original language	English (US)
Article number	1161
Journal	Cancers
Volume	12
Issue number	5
DOIs	https://doi.org/10.3390/cancers12051161
State	Published - May 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Acquired resistance
CTLA-4
Immune checkpoint blockade
Immune response
PD-1
T cells
Tumor immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3390/cancers12051161

OpenUrl availability

Full text

Cite this

@article{c279084775b84564b3eb204d0b6cc826,

title = "Acquired resistance to immune checkpoint blockade therapies",

abstract = "Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.",

keywords = "Acquired resistance, CTLA-4, Immune checkpoint blockade, Immune response, PD-1, T cells, Tumor immunology",

author = "Xianda Zhao and Dechen Wangmo and Matthew Robertson and Subbaya Subramanian",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = may,

doi = "10.3390/cancers12051161",

language = "English (US)",

volume = "12",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Acquired resistance to immune checkpoint blockade therapies

AU - Zhao, Xianda

AU - Wangmo, Dechen

AU - Robertson, Matthew

AU - Subramanian, Subbaya

PY - 2020/5

Y1 - 2020/5

N2 - Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.

AB - Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.

KW - Acquired resistance

KW - CTLA-4

KW - Immune checkpoint blockade

KW - Immune response

KW - PD-1

KW - T cells

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=85085033949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085033949&partnerID=8YFLogxK

U2 - 10.3390/cancers12051161

DO - 10.3390/cancers12051161

M3 - Review article

C2 - 32380703

AN - SCOPUS:85085033949

SN - 2072-6694

VL - 12

JO - Cancers

JF - Cancers

IS - 5

M1 - 1161

ER -

Acquired resistance to immune checkpoint blockade therapies

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this